Abstract
The development and progression of myocardial failure are heralded by the activation of circulating neurohormonal systems that modulate both vascular tone and renal retention of salt and water. In addition, the peripheral Circulation undergoes local changes in response to heart failure that are fundamental to the pathophysiology of this disease state. The fractional distribution of blood flow to the kidneys, limbs, and splanchnic beds decreases, whereas blood flow to the heart and brain is preserved.1,2 The diminished exercise capacity of limb muscles in patients with heart failure may be due, in part, to chronically diminished nutritive perfusion.3,4 Renal hypoperfusion and altered intrarenal hemodynamics may contribute to sodium and water retention.5,6 Previous chapters have focused on the mechanisms underlying systemic activation of the sympathetic nervous system, the renin-angiotensin system, as well as other circulatory neurohormones, such as arginine vasopressin and atrial natriuretic factor.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Leithe ME, Margorien RD, Hermiller JB, Unverferth DV, Leier CV. Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure. Circulation. 1984;69:57–64.
Zelis R, Flaim SF. Alterations in vasomotor tone in congestive heart failure. Prog Cardiovasc Dis. 1982;24:437–459.
Wiener DH, Maris J, Chance B, Wilson JR. Detection of skeletal muscle hypoperfusion during exercise using phosphorus-31 nuclear magnetic resonance spectroscopy. J Am Coll Cardiol. 1986;7:793–799.
Wilson JR, Wiener DH, Fink LI, Ferraro N. Vasodilatory behavior of skeletal muscle arterioles in patients with nonedematous chronic heart failure. Circulation. 1986;74:775–779.
Creager MA, Halperin AL, Bernard DB, et al. Acute regional circualtory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure. Circulation. 1981;64:483–489.
Cody RJ, Covit AB, Schaer GL, Laragh JH, Sealey JE, Feldschuh J. Sodium and water balance in chronic congestive heart failure. J Clin Invest. 1986;77:1441–1452.
Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373–376.
Ignarro LJ, Burns RE, Buga GM, Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein posesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res. 1987;61:866–879.
Palmer RMJ, Ferridge AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524–526.
Myers PR, Guerra R, Harrison DG. Release of NO and EDRF from cultured bovine aortic endothelial cells. Am J Physiol. 1989;256:H1030–H1037.
Ignarro LJ. Biological action and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res. 1989;65:1–21.
Cohen RA, Zitnay KM, Haudenschild CC, Cunningham LD. Loss of selective endothelial cell vasoactive functions in pig coronary arteries caused by hypercholesterolemia. Circ Res. 1988;63:903–910.
DeMey JG, Vanhoutte PM. Heterogeneous behavior of the canine arterial and venous wall: Importance of the endothelium. Circ Res. 1982;51:439–447.
Shimokawa H, Vanhoutte PM. Impaired endothelium-dependent relaxation to aggregating platelets and related vasoactive substances in porcine coronary arteries in hypercholesterolemia and atherosclerosis. Circ Res. 1989;64:900–914.
Rees DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA. 1989;86:3375–3378.
Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 1989;2:997–1000.
Luscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension. 1986;8:344–348.
Luscher TF, Vanhoutte PM, Raij L. Antihypertensive treatment normalizes decreased endothelium-dependent relaxations in rats with salt-induced hypertension. Hypertension. 1987;(suppl III):III193–III197.
Lockette W, Otsuka Y, Carretero OA. The loss of endothelium-dependent relaxation in hypertension. Hypertension. 1986;8:1161–1166.
Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelim-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22–27.
Ontkean MT, Gay R, Greenberg B. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res. 1991;69:1088–1096.
Kaiser L, Spickard RC, Olivier NB. Heart failure depresses endothelium-dependent responses in canine femoral artery. Am J Physiol. 1989;256:H962–H967.
Elsner D, Muntze A, Riegger AJR. The increase in total peripheral resistance by inhibition of EDRF-synthesis is attenuated in conscious dogs with heart failure.Circulation. 1990;III–591. Abstract.
Hildebrand FL Jr, Perrella MA, Burnett JD Jr. The role of endothelium-derived relaxing factor in experimental congestive heart failure. J Am Coll Cardiol. 1991; 17:281A. Abstract.
Main JS, Forster C, Armstrong PW. Inhibitory role of the coronary arterial endothelium to alpha-adrenergic stimulation in experimental heart failure. Circ Res. 1991;68:940–946.
Treasure CB, Vita JA, Cox DA, et al. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation. 1990;81:772–779.
Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation. 1991;84:1589–1596.
Kubo SH, Rector TS, Bank AJ, et al. Heart transplantation reverses abnormalities in endothelium dependent vasodilation of peripheral blood vessels in patients with heart failure. Circulation. 1991;84:II469.
Rubanyi GM. Cardiovascular Significance of Endothelium-derived Vasoactive Factors. Mount Kisco, NY: Futura Publishing, 1991.
Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure.Circulation. 1981;63:645–651.
Oliver JA, Sciacca R, Pinto J, Cannon PJ. Participation of the prostaglandins in the control of renal blood flow during acute reduction of cardiac output in the dog. J Clin Invest. 1981;67:229–237.
Friedman PL, Brown EJ Jr, Gunther S, et al. Coronary vasoconstrictor effect of indomethacin in patients with coronary artery disease. N Engl J Med. 1981;305:1171–1175.
Shebuski RJ, Aiken JW. Angiotensin II stimulation of renal prostaglandin synthesis elevated circulating prostacyclin in the dog. J Cardiovasc Pharmacol. 1980; 2:667–677.
Zusman RM, Keiser HR. Prostaglandin biosynthesis by rabbit renomedullary interstitial cells in culture: stimulation by angiotensin II, bradykinin and arginine vasopressin. J Clin Invest. 1977;60:215–223.
McGiff JC, Crawshaw K, Terragne NA, Malik KU, Lonigro AJ. Differential effect of noradrenaline and renal nerve stimulation on vascular resistance in the dog kidney and the release of a prostaglandin E-like substance. Clin Sci. 1972;42:223–233.
Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe heart failure: Relation to renin-angiotensin system and hyponatremia. N Engl J Med. 1984;310:347–352.
Swartz SL, Williams GH. Angiotensin-Converting enzyme inhibition and prostaglandins. Am J Cardiol. 1982;49:1405–1409.
Moore TJ, Crantz FR, Hollenbert NK, et al. Contribution of prostaglandins to the antihypertensive action of Captopril in essential hypertension. Hypertension. 1981;3:168–173.
Dzau VJ, Creager MA. Prostaglandins in congestive heart failure. In: Robertson JIS, ed. The Renin-Angiotensin System. London: Gower Medical; 1986:912–918.
Lavin RI, Jaffe EA, Weksler BB, Tack-Goldman K. Nitroglycerin stimulates synthesis of prostacyclin by cultured human endothelial cells. J Clin Invest. 1981;67:762–769.
Morcillio E, Reid PR, Dubin N, Ghodgaonkar R, Pitt B. Myocardial prostaglandin E release by nitroglycerin and modification by indomethacin. Am J Cardiol. 1980;45:53–57.
Rubin IJ, Lazar JD. Influence of prostaglandin synthesis inhibitors on pulmonary vasodilatory effects of hydralazine in dogs with hypoxic pulmonary vasoconstriction. J Clin Invest. 1981;67:193–200.
Yanagisawa M, Kurihara S, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415.
Wu-Wong JR, Budzik GP, Devine EM, Opgenorth TJ. Characterization of endothelin converting enzyme in rat lung. Biochem Biophys Res Commun. 1990;171:1291–1296.
Yanagisawa M, Masaki T. Endothelin, a novel endothelium-derived peptide: pharmacological activities, regulation and possible roles in cardiovascular control. Biochem Pharm. 1989;38:1877–1883.
Resink TJ, Hahn AWA, Scott-Burden T, Powell J, Weber E, Buhler FR. Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. Biochem Biophys Res Commun. 1990;168:1303–1310.
Brenner BM, Troy JL, Ballerinan BJ. Endothelium-dependent vascular responses: mediators and mechanisms. J Clin Invest. 1989;84:1373–1378.
Yoshizumi M, Kurihara H, Sugiyama T, et al. Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. Biochem Biophys Res Commun. 1989;161:859–864.
Masaki T, Kimura S, Yanagisawa M, Goto K. Molecular and cellular mechanism of endothelin regulation implications for vascular function. Circulation. 1991;84:1457–1468.
Marsden PA, Danthuluri NR, Brenner BM, Ballerman BM, Brock TA. Endothelin action on vascular smooth muscle involves inositol trisphosphate and calcium mobilization. Biochem Biophys Res Commun. 1989;158:86–93.
Resink TJ, Scott-Burden T, Buhler FR. Activation of phospholipase A2 by endothelin in cultured vascular smooth muscle cells. Biochem Biophys Res Commun. 1989;158:279–286.
Simonson MS, Wann S, Mene P, et al. Endothelin stimulates phospholipase C, Na+/H+ exchange, c-fos expression and mitogenesis in rat mesangial cells. J Clin Invest. 1989;83:708–712.
Ando K, Hirata YU, Shichiri M, Emori T, Marumo F. Presence of immunoreactive endothelin in human plasma. FEBS Lett. 1989;245:164–166.
Saito Y, Nakao K, Mukoyama M, Imura H. Increased plasma endothelin level in patients with essential hypertension. N Engl J Med. 1989;322:205.
Ogburn PL, Thompson RL, Lerman A, Burnett JC Jr. Endothelin elevation in normal preganancy and preeclampsia. Am J Obstet Gynecol. 1990;164:274.
Lerman A, Hallet JW, Heublein DM, Burnett JC Jr. A role for endothelin as a marker of diffuse atherosclerosis in the human. J Am Coll Cardiol. 1991;17:370A. Abstract.
King AJ, Pfeffer JM, Pfeffer MA, Brenner BM. Systemic hemodynamic effects of endothelin in rats. Am J Physiol. 1990;258:H787–H792.
Knuepfer MM, Han SP, Trapani AJ, Fok KF, Westfall TC. Regional hemodynamic and baroreflex effects of endothelin in rats. Am J Physiol. 1989;251 (Heart Circ Physiol 26):H918–H926.
Otsuka A, Mikami H, Katahira K, et al. Haemodynamic effect of endothelin, a novel potent vasconstrictor in dogs. Clin Exp Pharm Physiol. 1990;17:351–360.
Miller WI, Redfield MM, Burnett JC Jr. Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest. 1989;83:317–320.
Goetz KL, Wang BC, Madwed JB, Zhu JL, Leadley RJ Jr. Cardiovascular, renal and endocrine responses to intravenous endothelin in conscious dogs. Am J Physiol. 1988;255(Heart Circ Physiol 24):R1064–R1068.
Vigne P, Laxdunski M, Freiin C. The inotropic effect of endothelin-1 on rat atria involves hydrolysis of phosphatidylinositol. FEBS Lett. 1989;249:143–146.
Concas V, Laurent S, Brisac AM, Perret C, Safar M. Endothelin has potent direct inotropic and chronotropic effects in cultured heart cells. J Hypertens. 1989;7:S96–S97.
Hu JR, Hardorf RV, Lang RE. Endothelin has potent inotropic effects in rat atria. Eur J Pharmacol. 1988;158:275–278.
Lembeck F, Decrinis M, Pertl C, Amann R, Donner J. Effects of endothelin on the cardiovascular system and on smooth muscle preparations in different species. Naunyn-Scmiedeberg’s Arch Pharmacol. 1989;340:744–751.
Ishikawa T, Yanagisawa M, Kimura S, Goto K, Masaki T. Positive chronotropic effects of endothelin, a novel endothelium-derived vasconstrictor peptide. Pfluger Arch. 1988;413:108–110.
Kramer BK, Nishida M, Kelly RA, Smith TW. Endothelins: myocardial actions of a new class of cytokines. Circulation. 1992;85:350–356.
Stasch JP, Hirth-Kietrick C, Kazda S, Neuser D. Endothelin stimulates release of atrial natriuretic peptides in vitro and in vivo. Life Sci.. 1989;45:869–875.
Schiebinger RJ, Gomez-Sanchez CE. Endothelin: a potent stimulus of atrial natriuretic peptide secretion by superfused rat atria and its dependency on calcium. Endocrinology. 1990;127:119–125.
Cavero PG, Miller WL, Heublein DM, Margulies KB, Burnett JC. Endothelin in experimental congestive heart failure in the anesthetized dog. Am J Physiol. 1990;259:F312–F317.
Margulies KB, Hildebrand FL Jr, Lerman A, Perrella MA, Burnett JC Jr. Increased endothelin in experimental heart failure. Circulation. 1990;82:2226–2230.
Robertston R, Susawa T, Sugiura M, et al. Circulating endothelin levels: modulation by heart failure in man. Clin Res. 1990;38:414A. Abstract.
Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation. 1992;85: 510–517.
Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure.Circulation. 1992;85:504–509.
Ray SG, McMurray J, Morton JJ. Endothelin and atrial natriuretic factor in acute myocardial infarction. Circulation. 1990;82(suppl III):III–279. Abstract.
Cernacek P, Stewart D. Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. Biochem Biophys Res Commun. 1989;161:562–567.
Emori T, Hirata Y, Ohta K, Shichiri M, Marumo F. Secretory mechanism of immunoreactive endothelin in cultured bovine endothelial cells. Biochem Biophys Res Commun. 1989;160:93–100.
Wakenlin GE. Antibodies to renin as proof of the pathogenesis of sustained renal hypetension. Circulation. 1958;17:653–657.
Dzau VJ, Copelman RI, Barger AC, Haber E. Reninspecific antibody for study of cardiovascular homeostasis. Science. 1980;207:1091–1093.
Pals DT, Masucci FD, Sipos F, Denning GS. A specific competitive antagonist of the vascular action of angiotensin II. Circ Res. 1971;29:664–647.
Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin converting enzyme: new class of orally active antihypertensive agents. Science. 1977; 196:441–444.
Brunner HR, Gavras H, Waeber B, et al. Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med. 1979;90:19–23.
Wenting GJ, Blankestijn PJ, Pldermans D, et al. Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important. Am J Cardiol. 1987;59:92D–97D.
Kubo SH, Clark M, Laragh JH, Borer JS, Cody RJ. Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics. Am J Cardiol. 1987:60:1322–1328.
Creager MA, Faxon DP, Halperin SL, et al. Determinants of clinical response and survival in patients with congestive heart failure treated with Captopril. Am Heart J. 1982;104:1147–1153.
Dzau VJ, Re RN. Evidence for the existence of renin in the heart. Circulation. 1987;73(suppl I):I134–I136.
Philips MI, Stenstrom B. Angiotensin II in rat brain comigrates with authentic angiotensin II in high pressure liquid chromatography. Circ Res. 1985;56:212–219.
Deboben A, Inagami T, Ganten G. Tissue renin. In: Genest J, Kuchel O, Hamet P, eds. Hypertension. 2nd ed. New York: McGraw-Hill; 1983:194–209.
Field LS, McGowen RA, Dickensen DP, Gross KW. Tissue and gene specificity of mouse renin expression. Hypertension. 1984;6:597–603.
Lynch KR, Simnad VT, Ben-Ari ET, Maniatis T, Zinn K, Garrison JC. Localization of preangiotensinogen messenger RNA sequences in the rat brain. Hypertension. 1986;8:540–543.
Loudon M, Bing RF, Thurston H, Swales JD. Arterial wall uptake of renal renin and blood pressure control. Hypertension. 1983;5:629–634.
Oliver JA, Sciacca RR. Local generation of angiotensin II as a mechanism of regulation of peripheral vascular tone in the rat. J Clin Invest. 1984;4:1247–1251.
Dzau VJ, Gibbons GH. Autocrine-paracrine mechanisms of vascular myocytes in hypertension. Am J Cardiol. 1987;60:991–1031.
Rosenthal JH, Pfeiffer B, Mecheilor ML, Pschort J, Jacob ICM, Dahlheim H. Investigations of components of the renin-angiotensin system in rat vascular tissue. Hypertension. 1984;6:383–390.
Molteni A, Dzau VJ, Fallon JT, Haber E. Monoclonal antibodies as probes of renin gene expression.Circulation. 1984;70(suppl II):II–196. Abstract.
Mizuno K, Nakamaru M, Higashimori K, Inagami T. Local generation and release of angiotensin II in peripheral vascular tissue. Hypertension. 1988;11:223–229.
Aguirela G, Schirar A, Baukai A, Gatt KJ. Circulating angiotensin II and adrenal receptors after nephrectomy. Nature. 1981;289:507–509.
Campbell DJ. The site of angiotensin production. J Hypertens. 1985;3:730–737.
Admiraal PJJ, Darkx FHM, Jan Danser AH, Pierman H, Schalenkamp MADH. Metabolism and production of angiotensin II in different vascular beds in subjects with hypertension. Hypertension. 1990;15:44–55.
Shepherd JT, Vanhoutte PM, George E. Brown memorial lecture: local modulation of adrenergic neurotransmission. Circulation. 1981;64:655–666.
Longnecker DJ, Durcus MI, Donovan KR, Miller ED, Peach MJ. Saralasin dilates arterioles in SHR but not WKYrats. Hypertension. 1984;l(suppl I):106–110.
Riegger AJG, Lever AF, Miller JA, Morton JJ, Slack B. Correction of renal hypertension in the rat by prolonged infusion of saralasin. Lancet. 1977;2:1317–1319.
Okamura T, Miyazcki M, Inagemi T, Toda N. Vascular renin-angiotensin system in two-kidney, one clip hypertensive rats. Hypertension. 1986;8:560–565.
Unger T, Ganten D, Lang RE, Scholkens VA. Is tissue converting inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with two different compounds Hoe 398 and MD 421 in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1985;7:36–41.
Kaplan HR, Taylor DG, Olson SC, Andrews LK. Quinapril—a preclinical review of the pharmacology, pharmacokinetics, and toxicology. Angiology. 1989; 40:335–350.
Simon ACH, Levenson JA, Bouther JI, Safar ME. Comparison of oral MK 421 and propranolol in mild to moderate hypertension and their effects on arterial and venous vessels of the forearm. Am J Cardiol. 1984;53:781–783.
Dzau VJ, Safar MI. Large conduit arteries in hypertension: role of the vascular renin angiotensin system. Circulation. 1988;77:947–954.
Taugner R, Hackenthal E, Helmchen U, et al. The intrarenal renin-angiotensin system. An immunocyto-chemical study on the localization of renin, angiotensinogen, converting enzyme, and the angiotensins in the kidney of mouse and rat. Klin Wochenschr. 1982;60:1218–1222.
Taugner R, Hackenthal E, Rix E, Nibiling R, Poulsen K. Immunocytochemistry of the renin-angiotensin system: renin, angiotensinogen, angiotensin I, angiotensin II, and converting enzyme in the kidneys of mice, rats, and tree shrews.Kidney Int. 1982;22:S33–S43.
Dzau VJ, Kreisbert JI. Cultured glomerular mesangial cells contain renin: influence of calcium and isoproterenol. J Cardiol Pharmacol. 1986;8(suppl 10):S6-S10.
Dzau VJ, Ellison KE, Brody T, Ingelfinger J, Pratt RE. A comparative study of the distributions of renin and angiotensinogen messenger ribonucleic acids in rat and mouse tissues. Endocrinology. 1987;120:2334–2338.
Ingelfinger JR, Pratt RE, Ellison K, Dzau VJ. Sodium regulation of angiotensinogen mRNA expression in rat kidney cortex and medulla. J Clin Invest. 1986;78:1311–1315.
Ingelfinger JR, Fon EA, Ellison KE, Dzau VJ. Localization of the intratenal renin angiotensin system (RAS) by in situ hybridization of renin and angiotensinogen (Ang-n) mRNAs. Kidney Int. 1988;33:269. Abstract.
Ingelfinger JR, Zuo WM, Fon EA, Ellison KE, Dzau VJ. In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. J Clin Invest. 1990;85:417–423.
Soubrier F, Alhene-Gelas F, Hubert C, et al. Two putative active centers in human angiotensin I converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA. 1988;85:9386–9390.
Sakaguchi K, Chai SY, Jackson B, Johnston CI, Mendelsohn FAO. Inhibition of tissue angiotensin converting enzyme. Quantitation by autoradiography. Hypertension. 1988;11:230–238.
Ingelfinger JR, Anderson S, Hirsch AT, Dzau VJ, Brenner BM. Elevation of renal angiotensin converting enzyme (ACE) activity in nephrotic rats. American Society of Nephrology, Proceedings of 22nd Annual Meeting, Washington, DC, 1989;168A. Abstract.
Seikaly MG, Arant BS Jr, Seney FD Jr. Measurement of endogenous angiotensin levels in glomerular filtrate and proximal tubule fluid. American Society of Nephrology, Proceedings of 22nd Annual Meeting, Washington, DC, 1989;171A. Abstract.
Campbell DJ, Habener JF. Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest. 1986;78:31–39.
Ellison KE, Ingelfinger JR, Pivor M, Dzau VJ. Androgen regulation of rat renal angiotensinogen messenger RNA expression. J Clin Invest. 1989;83:1941–1945.
Schunkert H, Ingelfinger JR, Hirsch AT, et al. Evidence for tissue-specific activation of renal angiotensionogen mRNA expression in chronic stable experimental heart failure. J Clin Invest. 1992;90:1523–1529.
Creager MA, Halperin JL, Bernard DB, et al. Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure. Circulation. 1981;64:483–489.
Bank AJ, Kubo SH, Rector TS, Heifetz SM, Williams RE. Local forearm vasodilation with intra-arterial administration of enalaprilat in humans. Clin Pharmacol Ther. 1991;50:314–321.
Foult JM, Tavolaro O, Antony I, Nitenberg A. Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique. Circulation. 1988; 77:337–344.
Faxon DP, Halperin JL, Creager MA, Gavras H, Schick EC, Ryan TJ. Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of Captopril with observations on sustained oral therapy. Am Heart J. 1981;191:548–556.
Hoffman BB, Lefkowitz RJ. Alpha-adrenergic receptor subtypes. N Engl J Med. 1980;302:1390–1396.
Cotecchia S, Schwinn DA, Randall RR, Lefkowitz RJ, Caron MG, Kobilka BK. Molecular cloning and expression of the cDNA for the hamster alphal- adrenergic receptor. Proc Natl Acad Sci USA. 1988;85:7159–7163.
Schwinn DA, Lomasney JW, et al. Molecular cloning and expression of the cDNA for a novel alphar adrenergic receptor subtype. J Biol Chem. 1990; 265:8183–8189.
Han C, Abel PW, Minneman KP. Alpharadrenoceptor subtypes linked to different mechanisms for increasing intracellular Ca2+ in smooth muscle. Nature. 1987; 329:333–335.
Suzuki E, Tsujimoto G, Tamura K, Hashimoto K. Two pharmacologically distinct alphal-adrenoceptor subtypes in the contraction of rabbit aorta: each subtype couples with a different Ca2+ signalling mechanism and plays a different physiological role. Mol Pharmacol. 1990; 38:725–736.
Colucci WS, Gimbrone MA Jr, Alexander RW. Regulation of the postsynaptic alpha-adrenergic receptor in rat mesenteric artery. Effects of chemical sympathectomy and epinephrine treatment. Circ Res. 1981;48:104–111.
Tsujimoto G, Honda K, Hoffman BB, Hashimoto K. Desensitization of postjunctional alpha 1- and alpha 2-adrenergic receptor-mediated vasopressor response in rat harboring pheochromocytoma. Circ Res. 1987;61:86–98.
Colucci WS, Alexander RW. Norepinephrine-induced alteration in the coupling of alpharadrenergic receptor occupancy to calcium efflux in rabbit aortic smooth muscle cells. Proc Natl Acad Sci USA. 1986;83:1743–1746.
Izzo NJ Jr, Seidman CE, Collins S, Colucci WS. Alphar adrenergic receptor mRNA level is regulated by norepinephrine in rabbit aortic smooth muscle cells. Proc Natl Acad Sci USA. 1990;87:6268–6271.
Lurie KG, Tsujimoto G, Hoffman BB. Desensitization of alpha-1 adrenergic receptor-mediated vascular smooth muscle contraction. J Pharmacol Exp Ther. 1985; 234:147–152.
Goldberg MR, Robertson D. Evidence for the existence of vascular alpha2-adrenergic receptors in humans. Hypertension. 1984;6:551–556.
Lorenz W, Lomasney JW, Collins S, Regan JW, Caron MG, Lefkowitz RJ. Expression of three alpha2-adrenergic receptor subtypes in rat tissues: Implications for alpha2-receptor classification. Mol Pharmacol. 1990; 38:599–603.
Cotecchia S, Koblika BK, Daniel KW, et al. Multiple second messenger pathways of alpha-adrenergic receptor subtypes expressed in eukaryotic cells. J Biol Chem. 1990;265:63–69.
Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol. 1948;153:586–600.
Emorine LJ, Marullo S, Briend-Sutrean M-M, et al. Molecular characterization of the human β 3-adrenergic receptor. Science. 1989;245:1118–1121.
Lefkowitz RJ, Stadel JM, Caron MG. Adenylate cyclase-coupled β-adrenergic receptors.Annu Rev Biochem. 1983;52:159–186.
Bulbring E, Tomita T. Catecholamine action on smooth muscle. Pharmacol Rev. 1987;39:49–96.
Hertel C, Perkins JP. Receptor-specific mechanisms of desensitization of β-adrenergic receptor function. Mol Cell Endocrinol. 1984;37:245.
Kassis S, Fishman PH. Different mechanisms of desensitization of adenylate cyclase by isoproterenol and prostaglandin E1 in human fibroblasts. J Biol Chem. 1982;257:5312–5318.
Strasser RH, Lefkowitz RJ. Homologous desensitization of β-adrenergic receptor coupled adenylate cyclase. J Biol Chem. 1985;260:4561–4564.
Vatner DE, Vatner SF, Nejima J, et al. Chronic norepinephrine elicits desensitization by uncoupling the β-receptor. J Clin Invest. 1989;84:1741–1748.
Vatner DE, Vatner SF, Fujii AM, Homcy CJ. Loss of high affinity cardiac β-adrenergic receptors in dogs with heart failure. J Clin Invest. 1985;76:2259–2264.
Brodde O-E, Daul A, Michel-Reher M, et al. Agonistinduced desensitization of α-adrenoceptor function in humans.Circulation. 1990;81:914–921.
Rothwell NJ, Stock MJ, Sudera DK. Changes in tissue blood flow and β-receptor density of skeletal muscle in rats treated with the β 2-adrenoreceptor agonist clenbuterol. Br J Pharmacol. 1987;90:601–607.
Colucci WS, Alexander RW, Williams GH, et al. Decreased lymphocyte a-adrenergic agonist pirbuterol. N Engl J Med. 1981;305:185–190.
Wilson JR, Lanoce V, Frey MJ, Ferraro N. Arterial baroreceptor control of peripheral vascular resistance in experimental heart failure. Am Heart J. 1990;119:1122–1130.
Forster C, Carter SL, Armstrong PW. Alpha1 adrenoceptor activity in arterial smooth muscle following congestive heart failure. Can J Physiol Pharmacol. 1989;67:110–115.
Creager MA, Hirsch AT, Dzau VJ, Nabel EG, Cutler SS, Colucci WS. Baroreflex regulation of regional blood flow in congestive heart failure. Am J Physiol. 1990; 258:H1409–H1414.
Kubo SH, Rector TS, Heifetz SM, Cohn JN. Alpha2-receptor mediated vasoconstriction in patients with congestive heart failure. Circulation. 1989;80:1660–1667.
Gilson N, el Houda Bouanani N, Corsin A, Crozatier B. Left ventricular function and β-adrenoceptors in rabbit failing heart. Am J Physiol. 1990;258:H634–H641.
Fan T-H, Liang C-S, Kawashima S, Banerjee SP. Alterations in cardiac β-adrenoceptor responsiveness and adenylate cyclase system by congestive heart failure in dogs. Eur J Pharmacol. 1987;140:123–132.
Bristow MR, Hershberger RE, Port JD. β-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation. 1990;82:1–12.
Creager MA, Quigg RJ, Ren CJ, Roddy MA, Colucci WS. Limb vascular responsiveness to β-adrenergic receptor stimulation in patients with congestive heart failure. Circulation. 1991;83:1873–1879.
Walker BR. Evidence for a vasodilatory effect of vasopressin in the conscious rat. Am J Physiol. 1986;251: H34–H39.
Liard J-F. Cardiovascular effects associated with antidiuretic activity of vasopressin after blockade of its vasoconstrictor action in dehydrated dogs. Circ Res. 1986;58:631–640.
Hirsch AT, Dzau VJ, Majzoub JA, Creager MA. Vasopressin-mediated forearm vasodilation in normal humans; evidence for a vascular vasopressin V2 receptor. J Clin Invest. 1989;84:418–426.
Zusman RM, Keiser HR. Prostaglandin biosynthesis by rabbit renomedullary interstitial cells in tissue culture. Stimulation by angiotensin II, bradykinin, and arginine vasopressin. J Clin Invest. 1977;60:215–233.
Katusic ZS, Shepherd JT, Vanhoutte PM. Vasopressin causes endothelium-dependent relaxations of the canine basilar artery. Circ Res. 1984;55:575–579.
Yamane Y. Plasma ADH level in patients with chronic congestive heart failure. Jpn Circ J. 1968;32:745–759.
Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med. 1981;305:263–266.
Riegger GAJ, Liebau G, Koehsiek K. Antidiuretic hormone in congestive heart failure. Am J Med. 1982;72:49–52.
Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983;1:1385–1390.
Creager MA, Faxon DP, Cutler SS, Kohlmann O, Ryan TJ, Gavras H. The contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison to the renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol. 1986;7:756–765.
Mulinari RA, Gavra I, Wang YX, Franco R, Gavras H. Effects of a vasopressin antagonist with combined antipressor and antidiuretic properties in rats with left ventricular dysfunction. Circulation. 1990;81:308–311.
Stone CK, Liang C, Imai N, Sakamoto S, Sladek CD, Hood WB. Short-term hemodynamic effects of vasopressin V1-receptor inhibition in chronic right-sided congestive heart failure. Circulation. 1988;78:1251–1259.
Nicod P, Waeber B, Bussein J-P, et al. Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am J Cardiol. 1985;55:1043–1047.
Waldman SA, Rapoport RM, Murad F. Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem. 1984;259:14332–14334.
Winquist RJ, Faison SA, Waldman SA, Schwartz K, Murad F, Rapoport RM. Atrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle. Proc Natl Acad Sci USA. 1984;81:7661–7664.
Garcia R, Thibault G, Gutkowska J, Cantin M, Genest J. Changes of regional blood flow induced by atrial natriuretic factor (ANF) in conscious rats. Life Sci. 1985;36:1687–1692.
Ishihara T, Aisaka K, et al. Vasodilatory and diuretic actions of alpha-human atrial natriuretic polypeptide (alpha hANP). Life Sci. 1985;36:1205–1215.
Burnett JC Jr, Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986;231:1145–1147.
Raine AEG, Erne P, Burgisser F, et al. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med. 1986;31:533–537.
Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients. J Clin Invest. 1986;78:1362–1374.
Creager MA, Hirsch AT, Nabel EG, Cutler SS, Colucci WS, Dzau VJ. Responsiveness of atrial natriuretic factor to reduction in right atrial pressure in patients with chronic congestive heart failure. J Am Coll Cardiol. 1988;11:1191–1198.
Kohzuki M, Hodsman GP, Johnston CI. Attenuated response to atrial natriuretic peptide in rats with myocardial infarction. Am J Physiol. 1989;256:H533–H538.
Hirooka Y, Takeshita A, Imaizumi T, et al. Attenuated forearm vasodilatative response to intra-arterial atrial natriuretic peptide in patient with heart failure. Circulation. 1990;82: 147–153.
Zelis R, Mason DT, Braunwald E. A comparison of peripheral resistance vessels in normal subjects and in patients with congestive heart failure. J Clin Invest. 1968;47:960–970.
Creager MA, Quigg RJ, Ren CJ, Roddy M, Colucci WS. Limb vascular responsiveness to β-adrenergic receptor stimulation in patients with congestive heart failure. Circulation. 1991;83:1873–1879.
Longhurst J, Gifford W, Zelis R. Impaired forearm oxygen consumption during statis exercise in patients with congestive heart failure. Circulation. 1976;54:447–480.
Zelis R, Mason DT. Diminished forearm arteriolar dilator capacity produced by mineralocorticoid-induced salt retention in man.Circulation. 1970;41:589–592.
Zelis R, Delea CS, Coleman HN, Mason DT. Arterial sodium content in experimental congestive heart failure. Circulation. 1970;61:213–216.
Zelis R, Lee G, Mason DT. Influence of experimental edema on metabolically determined blood flow. Circ Res. 1974;34:482–490.
Sinoway L, Minotti J, Musch T, et al. Enhanced metabolic vasodilation secondary to diuretic therapy in decompensated congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1987;60:107–111.
Sinoway LI, Musch TI, Minotti JR, Zelis R. Enhanced maximal metabolic vasodilation in the dominant forearms of tennis players. J Appl Physiol. 1986;61:1076–1079.
Sinoway LI, Shenberger J, Wilson J, McLaughlin D, Musch T, Zelis R. A 30-day forearm work protocol increases maximal forearm blood flow. J Appl Physiol. 1987;62:1063–1067.
Sinoway LI, Minotti JR, Davis D, et al. Delayed reversal of impaired vasodilation in congestive heart failure after heart transplantation. Am J Cardiol. 1988;61:1076–1079.
Arnold JMO, Marchiori GE, Imrie JR, Bunton GL, Pflugfelden PW, Kostuk WJ. Large artery function in patients with chronic heart failure. Circulation. 1991;84:2418–2425.
Finkelstein SM, Cohn JN, Collins VR, Carlyle PF, Shelly WJ. Vascular hemodynamic impedance in congestive heart failure. Am J Cardiol. 1985;55:423–427.
Repine CJ, Nichols WW, Conti CR. Aortic input impedance in heart failure. Circulation. 1978;58:460–469.
Lage S, Kopel L, Monachini M, Coleman S, Polak J, Creager MA. Compliant properties of the carotid artery in congestive heart failure. Circulation. 1991;84:II–56.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag New York, Inc.
About this chapter
Cite this chapter
Hirsch, A.T., Creager, M.A. (1994). The Peripheral Circulation in Heart Failure. In: Hosenpud, J.D., Greenberg, B.H. (eds) Congestive Heart Failure. Springer, New York, NY. https://doi.org/10.1007/978-1-4613-8315-4_10
Download citation
DOI: https://doi.org/10.1007/978-1-4613-8315-4_10
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4613-8317-8
Online ISBN: 978-1-4613-8315-4
eBook Packages: Springer Book Archive